Skip to main content
EJNMMI Radiopharmacy and Chemistry
Fig. 7 | EJNMMI Radiopharmacy and Chemistry

Fig. 7

From: Preclinical evaluation of the theranostic potential of 89Zr/177Lu-labeled anti-TROP-2 antibody in triple-negative breast cancer model

Fig. 7

Micro-PET images in MDA-MB-231 tumor-bearing mice at different time points. A Representative MIP images of [89Zr]Zr-DFO-NY003 (5.55–7.4 MBq) in MDA-MB-231 model at different time points p.i.. B Representative MIP images of [89Zr]Zr-DFO-IgG (5.55 ~ 7.4 MBq) in the MDA-MB-231 model at different time points p.i.. C Representative MIP images of co-injection of [89Zr]Zr-DFO-NY003 (5.55 ~ 7.4 MBq) and cold NY003 in MDA-MB-231 model at different time points p.i.. D–G Quantitative ROI analysis showed that the tumor uptake of [89Zr]Zr-DFO-NY003 in MDA-MB-231 (n = 3) was significantly higher than that of blocking and [89Zr]Zr-DFO-IgG groups (P < 0.001). The radioactive uptake of the heart (blood), liver, and kidney gradually decreased within the time tested

Back to article page